State Street Corp raised its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 1.0% during the first quarter, Holdings Channel reports. The firm owned 16,085,954 shares of the medical research company’s stock after buying an additional 164,367 shares during the period. State Street Corp’s holdings in Thermo Fisher Scientific were worth $2,470,802,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. BB&T Securities LLC raised its position in shares of Thermo Fisher Scientific by 4.4% in the first quarter. BB&T Securities LLC now owns 89,837 shares of the medical research company’s stock worth $13,798,000 after buying an additional 3,819 shares during the period. Toronto Dominion Bank raised its position in shares of Thermo Fisher Scientific by 53.5% in the first quarter. Toronto Dominion Bank now owns 107,099 shares of the medical research company’s stock worth $16,450,000 after buying an additional 37,307 shares during the last quarter. Tompkins Financial Corp raised its position in shares of Thermo Fisher Scientific by 0.8% in the first quarter. Tompkins Financial Corp now owns 5,183 shares of the medical research company’s stock worth $733,000 after buying an additional 40 shares during the last quarter. Huntington National Bank raised its position in shares of Thermo Fisher Scientific by 6.9% in the first quarter. Huntington National Bank now owns 186,907 shares of the medical research company’s stock worth $28,708,000 after buying an additional 12,025 shares during the last quarter. Finally, Advisors Asset Management Inc. raised its position in shares of Thermo Fisher Scientific by 1.1% in the first quarter. Advisors Asset Management Inc. now owns 66,308 shares of the medical research company’s stock worth $10,185,000 after buying an additional 735 shares during the last quarter. Hedge funds and other institutional investors own 87.15% of the company’s stock.

Shares of Thermo Fisher Scientific Inc (NYSE:TMO) traded up 1.115% during mid-day trading on Friday, hitting $173.655. The company had a trading volume of 403,785 shares. The company has a market cap of $67.75 billion, a PE ratio of 30.253 and a beta of 1.06. The firm has a 50-day moving average of $176.85 and a 200-day moving average of $165.24. Thermo Fisher Scientific Inc has a 12 month low of $139.07 and a 12 month high of $182.87.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The firm had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.92 billion. During the same period in the prior year, the business posted $2.03 earnings per share. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. On average, analysts expect that Thermo Fisher Scientific Inc will post $9.24 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be given a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 annualized dividend and a yield of 0.35%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.45%.

WARNING: This report was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/11/thermo-fisher-scientific-inc-tmo-position-increased-by-state-street-corp.html.

A number of research analysts have weighed in on the company. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $197.00 price objective on the stock in a report on Tuesday, August 1st. BidaskClub lowered Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Bank of America Corporation restated a “buy” rating and issued a $210.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Cleveland Research upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a report on Thursday, July 20th. Finally, Barclays PLC restated an “overweight” rating and issued a $200.00 price objective (up previously from $190.00) on shares of Thermo Fisher Scientific in a report on Monday, July 17th. One research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average price target of $188.56.

In related news, CEO Marc N. Casper sold 20,000 shares of the stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the transaction, the chief executive officer now directly owns 269,279 shares in the company, valued at $46,528,718.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Stephen Williamson sold 2,500 shares of the stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $176.26, for a total value of $440,650.00. Following the transaction, the chief financial officer now owns 37,790 shares in the company, valued at $6,660,865.40. The disclosure for this sale can be found here. Insiders have sold 27,188 shares of company stock worth $4,702,223 over the last quarter. 0.49% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.